NCT00413153View on ClinicalTrials.gov

Metabolic Effects of Switching Kaletra to Boosted Reyataz

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
HIV Infections
Interventions
DRUG

atazanavir/ritonavir

atazanavir 300mg + ritonavir 100mg once daily

DRUG

lopinavir/ritonavir

patient remains on their pre-study dose of lopinavir/ritonavir

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00413153 - Metabolic Effects of Switching Kaletra to Boosted Reyataz | Biotech Hunter | Biotech Hunter